Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

NCT03951012 is registered in ClinicalTrials.gov with Muhammad Furqan as lead sponsor.

NCT NCT03951012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03951012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
Lead sponsor
Muhammad Furqan
Phase
Observational
Overall status
Terminated
Start date
April 15, 2019
Completion date
September 8, 2023
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer